{"id":"NCT04513652","sponsor":"American Genomics, LLC","briefTitle":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","officialTitle":"A Randomized, Double-Masked, Vehicle-Controlled, Parallel Evaluation of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-03","primaryCompletion":"2020-09-30","completion":"2020-12-17","firstPosted":"2020-08-14","resultsPosted":"2022-09-28","lastUpdate":"2022-09-28"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Anesthesia, Local"],"interventions":[{"type":"DRUG","name":"AG-920","otherNames":["articaine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AG-920","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.","primaryOutcome":{"measure":"The Number of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes","timeFrame":"5 minutes post dose","effectByArm":[{"arm":"AG-920","deltaMin":41,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37192994"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Instillation Site Pain","Conjunctival Hyperaemia","Dysgeusia"]}}